China In Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The China In Vitro Diagnostics Market is segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, Haematology, and Other Types), Product (Instrument, Reagent, and Other Products), Usability (Disposable IVD Devices and Reusable IVD Devices), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Other Applications), and End User (Diagnostic Laboratories, Hospitals and Clinics, and Other End Users).

Market Snapshot

China In-vitro Diagnostics Market Overview
Study Period: 2018-2026
Base Year: 2021
CAGR: 6.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Chinese in-vitro diagnostics market is projected to register a CAGR of 6.6% during the forecast period.

In-vitro diagnostics (IVDs) play an important role in the detection of infectious diseases. A large number of molecular assays and immunoassays are used for the detection of COVID-19. China represents one of the largest in-vitro diagnostics markets in the Asia-Pacific region, and this trend is expected to continue over the forecast period. Due to the upsurge of the geriatric population and the high burden of chronic and infectious diseases, like diabetes, cancer, and COVID-19, the studied market is slated to show significant growth, as these chronic disorders can be diagnosed and monitored using In-vitro diagnostics (IVD) products.

According to the World Health Organization (WHO), 102,762 COVID-19 cases were recorded as of March 2021, with 4,851 deaths in China. The increasing burden of the COVID-19 pandemic will lead to a high requirement of tests, which will boost the IVD market in the country.

The State Council issued a guideline to implement the country's Healthy China initiative to diminish the incidence of disability among elderly people aged between 65 and 74 years by 2022 by offering medical and health services. Such initiatives from the government are expected to boost market growth during the forecast period. However, a lack of proper reimbursement and stringent regulatory framework might hamper the growth of the market.

Scope of the Report

As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases.

The Chinese in vitro diagnostics market is segmented by test type (clinical chemistry, molecular diagnostics, immuno diagnostics, haematology, and other types), product (instrument, reagent, and other products), usability (disposable IVD devices and reusable IVD devices), application (infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease, nephrology, and other applications), and end user (diagnostic laboratories, hospitals and clinics, and other end users). The report offers the value (in USD million) for the above segments.

By Test Type
Clinical Chemistry
Molecular Diagnostics
Immuno Diagnostics
Other Types
By Product
Other Products
By Usability
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Autoimmune Disease
Other Applications
By End User
Diagnostic Laboratories
Hospitals and Clinics
Other End Users

Report scope can be customized per your requirements. Click here.

Key Market Trends

Molecular Diagnostics Segment Dominates the Chinese In Vitro Diagnostics Market

In diagnostics research, one of the most valuable advancements has been in the form of molecular diagnostic tools. The polymerase chain reaction is the most established forefront of molecular diagnostics. The real-time PCR products simultaneously detect viruses, bacteria, fungi, and parasites, allowing molecular laboratories to lower costs and drive better outcomes.

Molecular diagnostic tests are used for the detection of specific sequences in DNA or RNA (including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others) that may or may not be associated with any disease.

Molecular diagnostics are mainly used to diagnose infectious diseases, and with the rising burden and increasing spread of the COVID 19 pandemic, the segment is at its peak in the country. Molecular diagnostic assays are required for the detection of viral RNAs that are very specific to the SARS-CoV-2 virus, which causes COVID-19.

In addition, the rising burden of infectious disease can be attributed to the segment growth. For instance, According to the National Health Commission, nearly 1.71 million cases of infectious diseases were reported on the mainland for the month of December 2019. Approximately 288,739 cases were classified as Class B infectious diseases. Viral hepatitis, tuberculosis (TB), syphilis, scarlet fever, and gonorrhea accounted for 94% of these cases. Thus, with the rising importance given by clinical laboratories to diagnose diseases in the early stage of development, collaboration with domestic manufacturers, along with new product launches, the molecular diagnostics segment is expected to witness good growth over the forecast period in China.

China In-vitro Diagnostics Market Key Trends

Competitive Landscape

Many players in this market are trying to expand their product portfolio in order to top the global market. The companies focus on strategies, such as mergers and acquisitions, collaborations, and new product developments. For instance, in March 2021, OpGen announced that it had received regulatory approval from the Chinese National Medical Products Administration for its Curetis Unyvero system as an in vitro diagnostics instrument system. The submission of this was filed in 2019, which included the Unyvero A50 Analyzer, the Unyvero L4 Lysator, and the Unyvero C8 Cockpit. These factors are expected to propel market growth. Key players in the Chinese in vitro diagnostics market are Abbott Laboratories, Shanghai Kehua Bio-Engineering Co. Ltd, Autobio Diagnostics Co., Mindray Medical International Limited, and Maccura Biotechnology, among others.

Recent Developments

  • In December 2020, the NextSeq 550Dx received approval from China’s National Medical Products Administration (NMPA) for genetic testing and diagnosis, which will lead to improved patient outcomes by harnessing the power of next-generation sequencing.
  • In January 2020, BGI and its subsidiary MGI Tech announced that ultra-high-throughput sequencer DNBSEQ-T7, a metagenomic sequencing kit for coronaviruses, and 2019 novel coronavirus (2019-nCoV) reverse transcription PCR kit had received emergency use approval from China's National Medical Products Administration.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Burden of Chronic Diseases and Infectious Diseases

      2. 4.2.2 Increasing Use of Point-of-Care (POC) Diagnostics Spurring the IVD Market

      3. 4.2.3 Increasing Awareness and Acceptance of Personalized Medicine

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Proper Reimbursement

      2. 4.3.2 Stringent Regulatory Framework

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Test Type

      1. 5.1.1 Clinical Chemistry

      2. 5.1.2 Molecular Diagnostics

      3. 5.1.3 Immuno Diagnostics

      4. 5.1.4 Haematology

      5. 5.1.5 Other Types

    2. 5.2 By Product

      1. 5.2.1 Instrument

      2. 5.2.2 Reagent

      3. 5.2.3 Other Products

    3. 5.3 By Usability

      1. 5.3.1 Disposable IVD Devices

      2. 5.3.2 Reusable IVD Devices

    4. 5.4 By Application

      1. 5.4.1 Infectious Disease

      2. 5.4.2 Diabetes

      3. 5.4.3 Cancer/Oncology

      4. 5.4.4 Cardiology

      5. 5.4.5 Autoimmune Disease

      6. 5.4.6 Nephrology

      7. 5.4.7 Other Applications

    5. 5.5 By End User

      1. 5.5.1 Diagnostic Laboratories

      2. 5.5.2 Hospitals and Clinics

      3. 5.5.3 Other End Users


    1. 6.1 Company Profiles

      1. 6.1.1 Autobio Diagnostics Co.

      2. 6.1.2 F. Hoffmann-La Roche AG

      3. 6.1.3 Becton Dickinson & Company

      4. 6.1.4 Shanghai Kehua Bio-Engineering Co. Ltd

      5. 6.1.5 Abbott Laboratories

      6. 6.1.6 Thermofisher Scientific Inc.

      7. 6.1.7 QIAGEN NV

      8. 6.1.8 Xiamen Boson Biotech Co. Ltd

      9. 6.1.9 Maccura Biotechnology Co. Ltd

      10. 6.1.10 BGI Group

      11. 6.1.11 BioMerieux SA

      12. 6.1.12 Bio-Rad Laboratories Inc.

      13. 6.1.13 Danaher Corporation

      14. 6.1.14 Arkray Inc.

      15. 6.1.15 Mindray Medical International Limited

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The China In-vitro Diagnostics Market market is studied from 2018 - 2026.

The China In-vitro Diagnostics Market is growing at a CAGR of 6.6% over the next 5 years.

Autobio Diagnostics, Mindray Medical International Limited, Shanghai Kehua Bio-Engineering Co. Ltd., Maccura Biotechnology, Xiamen Boson Biotech are the major companies operating in China In-vitro Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!